Literature DB >> 34019179

CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas.

Inês Monteiro1, Edoardo Missiaglia1, Amedeo Sciarra1,2, João Vasco Santos3,4,5, Justine Bouilly1, Pedro Romero6, Christine Sempoux1, Laurence de Leval7.   

Abstract

CD73 converts AMP to adenosine, an immunosuppressive metabolite that promotes tumorigenesis. This study presents a systematic evaluation of CD73 expression in benign, hyperplastic, and neoplastic thyroid. CD73 expression was assessed by immunohistochemistry in 142 thyroid samples. CD73 was expressed in normal thyroid (3/6) and goiter (5/6), with an apical pattern and mild intensity. Apical and mild CD73 expression was also present in oncocytic cell adenomas/carcinomas (9/10; 5/8) and in follicular adenomas/carcinomas (12/18; 23/27). In contrast, papillary thyroid carcinomas featured extensive and intense CD73 staining (49/50) (vs. normal thyroid/goiter, p < 0.001). Seven of nine anaplastic carcinomas were CD73-positive with heterogeneous extensiveness of staining. Medullary and poorly differentiated carcinomas were mostly CD73-negative (1/6; 2/2). These results were corroborated by NT5E mRNA profiling. Papillary carcinomas feature enhanced CD73 protein and mRNA expression with distinct and intense staining, more pronounced in the invasive fronts of the tumors.

Entities:  

Keywords:  CD73; Immunohistochemistry; Papillary thyroid carcinoma; Thyroid adenoma; Thyroid carcinoma

Year:  2021        PMID: 34019179     DOI: 10.1007/s00428-021-03100-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  8 in total

1.  Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas.

Authors:  T Kondo; T Nakazawa; S-I Murata; R Katoh
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087

2.  [Lymphography in the evaluation of various radical operations].

Authors:  T Kolodziejski; A Klein; M Nowacki
Journal:  Pol Tyg Lek       Date:  1969-10-01

3.  CD73 expression in normal and pathological human hepatobiliopancreatic tissues.

Authors:  Amedeo Sciarra; Inês Monteiro; Christine Ménétrier-Caux; Christophe Caux; Benoit Gilbert; Nermin Halkic; Stefano La Rosa; Pedro Romero; Christine Sempoux; Laurence de Leval
Journal:  Cancer Immunol Immunother       Date:  2019-01-04       Impact factor: 6.968

4.  Extracellular ATP is Differentially Metabolized on Papillary Thyroid Carcinoma Cells Surface in Comparison to Normal Cells.

Authors:  Ana Paula Santin Bertoni; Rafael Paschoal de Campos; Marisa Tsao; Elizandra Braganhol; Tania Weber Furlanetto; Márcia Rosângela Wink
Journal:  Cancer Microenviron       Date:  2018-02-17

5.  Activity of ecto-5'-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes.

Authors:  Ana Paula Santin Bertoni; Paula Andreghetto Bracco; Rafael Paschoal de Campos; Bruna Schwengber Lutz; Beatriz Maria Assis-Brasil; Erika Laurini de Souza Meyer; Jenifer Saffi; Elizandra Braganhol; Tania Weber Furlanetto; Márcia Rosângela Wink
Journal:  Mol Cell Endocrinol       Date:  2018-09-02       Impact factor: 4.102

Review 6.  Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Authors:  Selena Vigano; Dimitrios Alatzoglou; Melita Irving; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; George Coukos
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

Review 7.  Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.

Authors:  Marco B Schaaf; Abhishek D Garg; Patrizia Agostinis
Journal:  Cell Death Dis       Date:  2018-01-25       Impact factor: 8.469

Review 8.  Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy.

Authors:  Samaneh Arab; Jamshid Hadjati
Journal:  Immune Netw       Date:  2019-08-27       Impact factor: 6.303

  8 in total
  1 in total

Review 1.  Purinergic signaling in thyroid disease.

Authors:  Ying Le; Donghui Lu; Meng Xue
Journal:  Purinergic Signal       Date:  2022-03-26       Impact factor: 3.765

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.